
Welcome to the BP learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation

Join Dr. Werth as she outlines how early diagnosis and treatment are critical to minimize risk and improve long term outcomes in patients with BP.
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP

Dr. Victoria Werth walks through the serious comorbidity risks associated with BP diagnosis

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
In this podcast, Dr. Teri Greiling and Dr. Daniel Butler discuss the enormous burden patients with bullous pemphigoid experience and how our understanding of the disease pathophysiology may help address unmet treatment needs.
In this ADVENT symposium at the 2024 EADV meeting, Professor Dedee Murrell reviews the current treatment guidelines for bullous pemphigoid (BP) and the emergence of targeted therapies including a highlight of the LIBERTY-BP ADEPT interim results.